Page History

Todd C. Zion, Ph.D., is the Co-founder, President and CEO of Akston Biosciences

Corporation, which is developing an injectable therapy for antigenspecific

prevention of Type 1 Diabetes. Prior to starting Akston Biosciences,

Todd C. Zion founded SmartCells, Inc. in 2003 to develop SmartInsulin™SmartInsulin,
the first glucose-regulated,

injectable formulation for treating diabetes.
As SmartCells’ President

president and CEO, He Zion was instrumental in raising $10
million in equity financing

from individual investors and $10 million in
grants to support research and clinical development. In December 2010,

Merck and Co. acquired SmartCells for over $500 million in cash and clinical

clinical milestone payments. He developed the SmartInsulin™ technology
as part of his doctoral thesis work at MIT. Prior to enrolling at MIT,
he worked as a polymer

development engineer at Eastman Kodak. Zion graduated from Cornell

University summa cum laude with a B.S. in Chemical Engineering. He is

currently an Associate Director at
now enjoys advising technology entrepreneurs through MIT’s Venture
Mentoring Service . He and also

serves on a number of advisory boards including
those of the Beth Israel

Deaconess Medical Center, Joslin Diabetes Center, and the Cornell Engineering

College Council. He is also active in his community serving as the head

of Devereux School and President of Dollars for Scholars.

  and the CNY
Biotech Accelerator.

72 Nanepashemet St.
Marblehead, MA 01945
857 389-2273
todd@toddzion.com